Cepmox: Advanced Broad-Spectrum Antibiotic Therapy
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.19 (0%) | 🛒 Add to cart |
| 60 | $0.72 | $82.39 $43.20 (48%) | 🛒 Add to cart |
| 90 | $0.54 | $123.58 $48.23 (61%) | 🛒 Add to cart |
| 120 | $0.46 | $164.77 $55.26 (66%) | 🛒 Add to cart |
| 180 | $0.40 | $247.16 $71.33 (71%) | 🛒 Add to cart |
| 270 | $0.35 | $370.73 $95.45 (74%) | 🛒 Add to cart |
| 360 | $0.32
Best per pill | $494.31 $115.54 (77%) | 🛒 Add to cart |
Cepmox (amoxicillin/clavulanate potassium) is a potent, combination beta-lactam/beta-lactamase inhibitor antibiotic designed to overcome resistant bacterial infections. It delivers enhanced bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens, including those producing beta-lactamase enzymes. Clinically trusted for its reliable pharmacokinetic profile and high tissue penetration, Cepmox is a first-line choice for moderate to severe community-acquired infections. Its dual-action formulation ensures comprehensive coverage while minimizing the risk of treatment failure due to enzymatic resistance.
Features
- Combination formulation: amoxicillin 875 mg/clavulanate potassium 125 mg per tablet
- Broad-spectrum activity against beta-lactamase-producing organisms
- High oral bioavailability (>90%) with rapid absorption
- Twice-daily dosing regimen for improved adherence
- Stable across varying gastric pH levels
- Manufactured under cGMP standards with consistent dissolution profiles
Benefits
- Effectively eradicates resistant pathogens that single-agent antibiotics cannot target
- Reduces the need for step-up therapy or hospitalization in appropriate cases
- Provides rapid onset of action with measurable clinical improvement within 48–72 hours
- Low incidence of acquired resistance due to clavulanate’s irreversible beta-lactamase inhibition
- Supports shorter treatment durations in properly diagnosed infections
- Minimizes relapse rates in respiratory, urinary, and skin structure infections
Common use
Cepmox is indicated for the treatment of infections caused by susceptible strains of designated microorganisms, including lower respiratory tract infections (e.g., bronchitis, pneumonia), otitis media, sinusitis, skin and skin structure infections, and urinary tract infections. It is also used in dental infections and animal bite wounds where mixed flora including beta-lactamase producers are suspected. Off-label uses may include prophylaxis in certain surgical procedures and treatment of Lyme disease in specific clinical scenarios.
Dosage and direction
The usual adult dose is one 875 mg/125 mg tablet every 12 hours. For more severe infections, dosing may be increased to one tablet every 8 hours. Take with food to enhance absorption and minimize gastrointestinal upset. Treatment should generally continue for a minimum of 5–7 days, though certain infections (e.g., chronic bronchitis, pyelonephritis) may require 10–14 days. Dosage adjustment is required in renal impairment: for CrCl 10–30 mL/min, 500 mg/125 mg every 12 hours; for CrCl <10 mL/min, 500 mg/125 mg every 24 hours.
Precautions
Use with caution in patients with hepatic impairment; monitor liver function periodically during prolonged therapy. May cause fungal or bacterial superinfection, including pseudomembranous colitis. Avoid in patients with mononucleosis due to high risk of rash. Use during pregnancy only if clearly needed (Category B). Amoxicillin and clavulanate are excreted in breast milk; consider temporary discontinuation of nursing. Perform culture and susceptibility testing prior to and during therapy when warranted.
Contraindications
History of hypersensitivity to amoxicillin, clavulanate, or any other beta-lactam antibiotic. Contraindicated in patients with a history of Cepmox-associated cholestatic jaundice or hepatic dysfunction. Do not use in patients with phenylketonuria (contains phenylalanine). Concomitant use with disulfiram or alcohol is contraindicated due to risk of reaction.
Possible side effect
Common: diarrhea, nausea, vomiting, abdominal discomfort, skin rash, candidiasis. Less common: elevated liver enzymes, headache, dizziness, vaginitis. Rare: hepatitis, cholestatic jaundice, Stevens-Johnson syndrome, toxic epidermal necrolysis, hemolytic anemia, thrombocytopenia, agranulocytosis, interstitial nephritis, anaphylaxis. Clavulanate component is frequently associated with cholestatic events in prolonged use.
Drug interaction
Probenecid decreases renal tubular secretion of amoxicillin—concomitant use may increase and prolong blood levels. Allopurinol increases incidence of skin rash. May reduce efficacy of oral contraceptives; advise alternative contraception. Concurrent use with warfarin may enhance anticoagulant effect—monitor INR. Tetracyclines and other bacteriostatic antibiotics may antagonize bactericidal effect.
Missed dose
Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double the dose to make up for the missed one. Maintaining consistent blood levels is critical for antibacterial efficacy and resistance prevention.
Overdose
Symptoms may include gastrointestinal distress (nausea, vomiting, diarrhea), electrolyte imbalance, and crystaluria. Management is supportive; maintain hydration and electrolyte balance. Hemodialysis may enhance elimination of both components. There is no specific antidote.
Storage
Store at controlled room temperature (20–25°C). Keep in original container, tightly closed, and protect from moisture and light. Keep out of reach of children. Do not use after expiration date printed on packaging.
Disclaimer
This information is intended for healthcare professionals. Not for consumer use. Always consult a qualified medical practitioner for diagnosis and appropriate treatment. Dosage and indications may vary based on individual patient factors, local resistance patterns, and clinical guidelines. Self-medication with antibiotics is dangerous and contributes to antimicrobial resistance.
Reviews
“Cepmox remains a workhorse in outpatient infectious disease management. Its reliability in treating polymicrobial infections, especially in diabetic foot infections and complicated UTIs, is well-supported by both clinical experience and surveillance data.” — Dr. Elena Rostova, Infectious Disease Specialist
“The twice-daily dosing significantly improves patient compliance compared to older q8h regimens. I’ve observed excellent clinical response rates in pediatric otitis media when amoxicillin failure is suspected.” — Dr. Mark Higgins, Pediatrician
“While effective, clinicians should remain vigilant for hepatic adverse events, particularly in elderly patients on prolonged courses. Routine LFT monitoring is advisable beyond 10 days of therapy.” — Clinical Pharmacologist, University Hospital